Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Consorcio ARA S. A. B. de C. V
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Urbanization And Population Trends Will Drive Affordable Housing Demand
Key Takeaways Strong positioning in middle-income housing, sustainable practices, and a large land bank underpin ARA's potential for sustained revenue growth and margin expansion. Favorable demographic trends and financial strength enable ARA to pursue growth initiatives and shareholder returns despite sector volatility.
View narrative
Mex$13.10
FV
76.0% undervalued
intrinsic discount
6.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Elekta
AN
AnalystHighTarget
Consensus Narrative from 13 Analysts
Growing Elderly Populations And Emerging Markets Will Fuel Radiotherapy Demand
Key Takeaways Global aging and rising cancer rates, combined with Elekta's AI-driven platforms, position the company for resilient, long-term growth in both revenue and recurring cash flow. Expansion into emerging markets and advances in integrated precision therapies provide significant underappreciated growth opportunities and structural margin improvement.
View narrative
SEK 90.65
FV
47.1% undervalued
intrinsic discount
8.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
PTC Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 16 Analysts
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
Key Takeaways Accelerated adoption of key therapies, global expansion, and a robust rare disease portfolio position the company for sustained revenue and margin growth. Strategic partnerships, disciplined operations, and business development readiness enhance flexibility for value-creating deals and expanding innovative treatment pipelines.
View narrative
US$105.36
FV
53.7% undervalued
intrinsic discount
-8.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Ambarella
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Autonomous Vehicles And Edge AI Will Expand Secular Opportunities
Key Takeaways Expansion into edge AI and scalable infrastructure products could drive sustainable, above-expected growth in revenue, margins, and free cash flow across multiple high-value markets. Recurring software and services income, combined with a resilient supply chain and growing platform ecosystem, positions Ambarella for lasting market leadership in AI-powered solutions.
View narrative
US$95.00
FV
29.5% undervalued
intrinsic discount
17.38%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Recursion Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
OS 20 Will Accelerate AI Drug Discovery And Clinical Milestones
Key Takeaways Recursion's advanced AI-driven platforms and proprietary models position it for industry-leading speed, scale, and precision in drug discovery, enabling superior margins and accelerated R&D productivity. Strategic partnerships and innovation cycles establish Recursion as a key player in biopharma pipelines, increasing its attractiveness for major collaborations and potential acquisitions.
View narrative
US$10.00
FV
42.3% undervalued
intrinsic discount
82.23%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 15 hours ago
author updated this narrative
Alignment Healthcare
AN
AnalystHighTarget
Consensus Narrative from 10 Analysts
Digital Health And Aging Population Will Advance Coordinated Care
Key Takeaways Rapid market share gains and scalable operations, aided by top clinical performance and digital health innovations, will boost long-term revenue and earnings power. Unique holistic care model enhances member retention and satisfaction, driving sustainable revenue growth and improving margins over multiple years.
View narrative
US$23.00
FV
34.6% undervalued
intrinsic discount
34.32%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Cyrela Brazil Realty Empreendimentos e Participações
AN
AnalystHighTarget
Consensus Narrative from 13 Analysts
Urbanization And Digitalization Will Elevate Brazil Housing Opportunities
Key Takeaways Strong brand, digital investments, and dominant urban presence set Cyrela up for outlier growth and sustained margin expansion despite sector challenges. Superior execution and market consolidation offer a rare chance to capture share, with rapid launches and cost discipline driving earnings far above peers.
View narrative
R$40.00
FV
35.5% undervalued
intrinsic discount
11.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
PVA TePla
AN
AnalystHighTarget
Consensus Narrative from 10 Analysts
AI And Renewable Trends Will Fuel Semiconductor Advancements
Key Takeaways Leading advances in metrology, materials, and defect detection position the company for faster profitability, premium pricing, and sustained growth beyond consensus expectations. Expansion into diverse industries and regions, supported by advanced customer infrastructure, will increase revenue stability, resilience, and operating leverage.
View narrative
€29.00
FV
17.3% undervalued
intrinsic discount
16.76%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Life Healthcare Group Holdings
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Aging Population And Digital Health Will Redefine Healthcare
Key Takeaways Accelerating hospital expansion and digital health investments are set to drive sustained growth and open new high-margin revenue streams. Strong balance sheet and efficient capital management enable aggressive geographic expansion and high returns compared to competitors.
View narrative
R18.60
FV
25.6% undervalued
intrinsic discount
4.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 15 hours ago
author updated this narrative
Value any company in seconds
Popular companies